Access to Radiation Therapy Expands, Especially in Densely Populated Areas

Article

Researchers found there has been a 17% growth in radiation therapy facilities over the last 15 years, with expansion specifically improving for those who already live near such facilities.

There has been a 17% growth in radiation therapy (RT) facilities over the last 15 years, with expansion specifically improving for those who already live near RT facilities, according to a study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.1

Based on a 50-mile threshold, researchers found that 4.5% of the US population still has limited geographic access to RT, suggesting a need for interventions to mitigate this disparity.

“Radiation therapy is one of the primary treatments for cancer, but one in 20 Americans lives quite far from a radiation therapy clinic,” lead author Sean Maroongroge, MD, MBA, a radiation oncology resident at The University of Texas MD Anderson Cancer Center in Houston, said in a press release.2 "If we do not incentivize or find ways to help people who live farther from treatment sites get access to radiation therapy, then this gap may continue to widen over time."

"With the growth of telemedicine, especially during the COVID-19 pandemic, there are a lot of ways we can think about transforming care, but radiation therapy delivery requires patients to come to a treatment facility," Maroongroge added.

Of note, the last time a comprehensive inventory of US RT facilities was completed was in 2005, based on data from state regulatory agencies and international dosimetric quality assurance bodies. Researchers therefore sought to update this database to include changes observed over the last 15 years.

For this study, the investigators compiled data from state regulatory agencies regarding the location of facilities that deliver RT for human medical treatment from 2018 to 2020. Additionally, data was also compiled from the databases of 2 independent peer review organizations that provide nationwide dosimetry auditing for radiation therapy units, including Radiation Dosimetry Services (RDS) and the Imaging and Radiation Oncology Core (IROC).

In 2020, a total of 2332 US RT facilities were reported compared to 1987 in 2005, which represents a 17% growth in facilities over nearly 15 years. More specifically, 33% (662/1987) of sites in the prior dataset did not exist in the updated dataset based on geolocation with latitude and longitude coordinates alone.

However, 25.6% of county centroids were found to be currently located within 12.5 miles of a RT facility, while 16.9% are located more than 50 miles away. In addition, a third of sites demonstrated geographic turnover over time, representing facility closures, movement, or methodological differences in data capture.

Ultimately, based on population attribution to county centroids, nearly 70% of the US population lives within 12.5 miles of an RT facility; a 65% increase from that observed in 2005.

"The disproportionate growth suggests that new sites are being built closer to people who are already close, rather than closer to people who are farther away,” said Maroongroge. “It could be that those are the people who need access the most, and we need to think carefully about how to help these patients get access to care.”

"The most unfortunate cases I see are when nonclinical factors undermine the type of care patients receive," Maroongroge continued. "I have patients who just say that it's just not feasible for them to get radiation if they have to travel a long distance. The financial stress and the weight of logistical burdens can't be understated in terms of how much they dominate patients' lives."

Moving forward, the researchers intend to validate their results with additional datasets to better understand the populations who are at risk and identify potential levers to create change. Further, access for people who live close to facilities is also an area of interest.

"There are a lot of questions in terms of policy and perhaps even technology that may help us deliver better care to underserved patients," Maroongroge concluded.

References:

1. Maroongroge S, Wallington DG, Taylor PA, et al. Geographic Access to Radiation Therapy in the United States. Presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting. Abstract #: 203.

2. Access to radiation therapy has grown, especially in densely populated areas [news release]. Arlington, Virginia. Published October 27, 2020. Accessed November 2, 2020. https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2020/Access-to-radiation-therapy-has-grown,-especially

Recent Videos
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Related Content